An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice - PubMed (original) (raw)

. 2001 Aug 28;98(18):10320-5.

doi: 10.1073/pnas.171060098. Epub 2001 Aug 14.

R T Lee, C Politis, I Hennessy, A Crane, J Puc, M Neshat, H Wang, L Yang, J Gibbons, P Frost, V Dreisbach, J Blenis, Z Gaciong, P Fisher, C Sawyers, L Hedrick-Ellenson, R Parsons

Affiliations

An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice

K Podsypanina et al. Proc Natl Acad Sci U S A. 2001.

Abstract

PTEN phosphatase acts as a tumor suppressor by negatively regulating the phosphoinositide 3-kinase (PI3K) signaling pathway. It is unclear which downstream components of this pathway are necessary for oncogenic transformation. In this report we show that transformed cells of PTEN(+/-) mice have elevated levels of phosphorylated Akt and activated p70/S6 kinase associated with an increase in proliferation. Pharmacological inactivation of mTOR/RAFT/FRAP reduced neoplastic proliferation, tumor size, and p70/S6 kinase activity, but did not affect the status of Akt. These data suggest that p70/S6K and possibly other targets of mTOR contribute significantly to tumor development and that inhibition of these proteins may be therapeutic for cancer patients with deranged PI3K signaling.

PubMed Disclaimer

Figures

Figure 1

Figure 1

Pten+/− mice develop pheochromocytomas of the adrenal medulla. Morphology of the wild-type adrenal (A) and the Pten+/− adrenal containing a pheochromocytoma (B). (Magnification, ×40.) The normal medulla can be seen in the center of the wild-type adrenal cortex. Paraffin sections were stained with hematoxylin/eosin. PTEN+/− animals (mutant) have elevated levels of serum norepinephrine (C) and epinephrine (D) relative to wild type.

Figure 2

Figure 2

Increased proliferation in the neoplastic regions of Pten+/− uteri and adrenals. Mice were injected with 125 mg/kg of BrdUrd for 1 h before death and sections were stained with an antibody recognizing BrdUrd. (A) Proliferation index in Pten+/+ (□) and Pten +/− (■) uteri was calculated by comparing the proliferation index of the secretory epithelium in wild type with that of the CAH. (B) Proliferation index in normal (□) and transformed (■) regions of cysts of Pten+/− uteri. BrdUrd-positive cells were counted per total number of nuclei. (C) Proliferation index of wild-type (□) and +/− (■) adrenal medulla. Error bars indicate SD. Examples BrdUrd staining of the wild-type (D) and Pten+/− (E) medulla. Increased BrdUrd incorporation can be seen in E relative to D.

Figure 3

Figure 3

Neoplastic lesions in Pten+/− uteri have lower levels of Pten, and higher active Akt. (A) Loss of heterozygosity in hyperplastic lesions of the endometrium. Products from wild-type and mutant Pten alleles are amplified in a duplex reaction. Controls consist of products generated from tail DNA isolated from Pten heterozygous (lane 1) and wild-type (lane 2) mice. Lanes 3, 4, and 5 are amplified products from microdissected, hyperplastic endometrial lesions from three Pten heterozygous mice at 32 weeks of age. Loss of the wild-type Pten allele is present in one lesion (lane 3), and both alleles are retained in the other two lesions (lanes 4 and 5). (B) Loss of heterozygosity in Pten+/− adrenals. Adrenal DNA was prepared from six Pten+/− mice. After probing the wild-type (wt) and mutant alleles (mut) (arrowheads), we observed that five of the six Pten+/− adrenals had undergone loss of heterozygosity. Control (+/−) and wild-type DNA (+/+) were prepared from tails. (C_–_E) Transition zone in Pten+/−-transformed uterine cysts. Slides were stained with hematoxylin/eosin (C), rabbit polyclonal anti-PTEN (D), and rabbit polyclonal anti-phospho-AKT (Ser-473) (E). (Magnification, ×600.) (F and G) Altered PTEN and phospho-AKT expression are detected in the adrenal medulla. Reduced PTEN staining correlates with transformation and phospho-AKT staining. (F) A small representative focus of reduced PTEN expression in a Pten+/− adrenal medulla. Notice that most PTEN staining within the medullary cells occurs in the nucleus. (G) A small focus of increased phospho-AKT staining correlates with reduced PTEN expression. (Magnification, ×600.) Cortex (C) stains nonspecifically for PTEN and phospho-AKT.

Figure 4

Figure 4

S6K activity but not AKT phosphorylation can be inhibited with CCI-779. (A) S6K activity in Pten+/− (●), Pten+/− treated with CCI-779 for 3 days (○), and Pten+/+ (□) uterine lysates. Protein concentration was measured from the soluble fraction, and samples were normalized for equal protein concentration before the immunoprecipitation and measurement of S6K activity. (B) Short-term CCI-779 treatment reduces the BrdUrd incorporation index. BrdUrd incorporation index in mock (■)- and drug (□)-treated Pten+/− uterine epithelium treated for 3 days with vehicle or CCI-779. (C) Phosphorylated S6K levels in 293 cell line and mouse uterine lysates. (Lanes 1 and 2) 293 cells pulsed with epidermal growth factor or starved. Note reduced mobility of S6K in lane 1. Pten+/+ (lanes 3 and 4) and Pten+/− (lanes 5–8) uterine lysates analyzed on an 8% polyacrylamide gel. Frozen uteri were ground and transferred into loading SDS buffer, and protein concentrations were normalized by anti-MAPK signal. A slower migrating band was seen in lysates of mice that were not treated with CCI-779 (lanes 7 and 8). This band was not present in Pten+/− lysates of mice treated with CCI-779 for 3 days (lanes 5 and 6) or in treated or untreated wild-type lysates (lanes 3 and 4). (D) Uterine (Upper) and adrenal (Lower) lysates from wild-type (+/+) and mutant animals (+/−) were resolved on a 4–20% gradient gel, blotted, and probed with anti-phospho-473 and total AKT antibodies. Each sample was collected from a Pten+/− mouse injected with either diluent or CCI-779 (Drug) for 3 days.

Figure 5

Figure 5

Long-term CCI-779 treatment prevents tumor growth and proliferation in Pten+/− without affecting Akt activity. (A) Size of neoplastic lesions in mock, untreated (none) and CCI-779-treated (CCI) uteri. All mice are Pten+/− females and average age of each cohort is indicated. (B) Size of the untreated (none) wild-type (wt), untreated Pten+/−, mock-treated Pten+/−, and CCI-779-treated (CCI) Pten+/− adrenal medullas. (C) Proliferation in mock (■)- and drug (□)-treated uteri. BrdUrd-positive cells were counted per total number of nuclei in CAH. (D) Proliferation in mock-treated Pten+/− (■) and CCI-779-treated Pten+/− (□) adrenal medullas. (E and F) Phosoho-473 Akt levels in the mock (E)- and drug (F)-treated uteri. (Magnification, ×400).

Comment in

Similar articles

Cited by

References

    1. Ali I U, Schriml L M, Dean M. J Natl Cancer Inst. 1999;91:1922–1932. - PubMed
    1. Cantley L C, Neel B G. Proc Natl Acad Sci USA. 1999;96:4240–4245. - PMC - PubMed
    1. Stambolic V, Suzuki A, de la Pompa J L, Brothers G M, Mirtsos C, Sasaki T, Ruland J, Penninger J M, Siderovski D P, Mak T W. Cell. 1998;95:29–39. - PubMed
    1. Sun H, Lesche R, Li D M, Liliental J, Zhang H, Gao J, Gavrilova N, Mueller B, Liu X, Wu H. Proc Natl Acad Sci USA. 1999;96:6199–6204. - PMC - PubMed
    1. Huang H, Potter C J, Tao W, Li D M, Brogiolo W, Hafen E, Sun H, Xu T. Development (Cambridge, UK) 1999;126:5365–5372. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources